{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-079152","form_type":"8-K","ticker":"FLGT","cik":"0001674930","company_name":"Fulgent Genetics, Inc.","filed_at":"2026-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.859316+00:00","generated_at":"2026-05-15T23:05:32.548311+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Fulgent Genetics Q4 2025 revenue $83.3M (+9% YoY); GAAP loss $0.76/share, Non-GAAP income $0.16/share","bullets":["Q4 2025 revenue of $83.3M, up 9% year-over-year; full-year revenue $322.7M, up 14%.","GAAP net loss $23.4M ($0.76 loss per share) in Q4; full-year GAAP loss $60.5M ($1.97 per share).","Non-GAAP net income $5.2M ($0.16 per share) in Q4; full-year non-GAAP income $13.2M ($0.42 per share).","Cash, equivalents, restricted cash, and marketable securities totaled $705.5M at year-end, plus $106.3M anticipated tax refund.","Adjusted EBITDA loss of $4.5M in Q4 and $9.4M for full year 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-079152","json":"https://secwatch.observer/filing/0001193125-26-079152.json","markdown":"https://secwatch.observer/filing/0001193125-26-079152.md","text":"https://secwatch.observer/filing/0001193125-26-079152.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1674930/000119312526079152/0001193125-26-079152-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1674930/000119312526079152/flgt-20260227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:05:32.548311+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}